Eloralintide
A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor.
The amylin note played alone and in tune — selective at its receptor, and the first proof that a non-incretin signal can carry GLP-1-class weight loss by itself.
Identity
- Class
- Selective long-acting amylin analog (acylated 37 aa peptide)
- Source
- Synthetic; engineered amylin analog (Eli Lilly, LY3841136)
- Receptor
- Amylin receptors (calcitonin receptor + RAMP), AMY1-selective
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Eloralintide is a 37-residue amylin analog engineered for selectivity at the amylin receptor over the bare calcitonin receptor, stabilised against aggregation, and carrying a C20 fatty-diacid chain that binds albumin for a roughly two-week half-life. At the receptor it reproduces amylin's biology — slowed gastric emptying, suppressed post-meal glucagon, central satiety — without any GLP-1 receptor activity. It is the cleanest test yet of how far the amylin axis can go on its own, and is also being paired with tirzepatide. It is investigational.
In depth
Cagrilintide proved that the amylin axis could be stretched to a weekly clock. Eloralintide asks a sharper question: what does the amylin signal do when it is played cleanly, on its own, with nothing else in the syringe? Native amylin signals through a receptor it borrows — the calcitonin receptor dressed in a RAMP accessory protein — and most amylin analogs, cagrilintide included, also activate the undressed calcitonin receptor. Eloralintide was engineered to prefer the dressed form. That selectivity is the molecular point of the drug, and it is why its results are read as a verdict on amylin specifically rather than on a blend.
The engineering is the familiar long-acting playbook applied to a hormone that resists it. Thirty-seven residues, the fibril-forming tendency stabilised out, and a C20 fatty-diacid chain on a lysine that latches the peptide onto albumin, buying a half-life of roughly two weeks from a hormone that natively lasts minutes. The phase 2 readout was what made the molecule a headline: at 48 weeks, weekly doses from 1 to 9 milligrams took off between about a tenth and a fifth of body weight, against essentially nothing on placebo. That upper figure sits where semaglutide and tirzepatide sit — without the drug ever touching an incretin receptor.
What comes with it is the thing the whole amylin field is betting on: gut side effects that were mostly mild to moderate, with no GLP-1 arm in the trial to prove the edge directly. The next experiment is the obvious one. Paired with tirzepatide as EloraTZP, in people with obesity and type 2 diabetes, the combination reached about 23% weight loss at 48 weeks where tirzepatide alone reached about 15% — two satiety signals from two different receptor families, stacked. Phase 3 trials of eloralintide alone and of a co-formulated pair are where that arithmetic gets tested at scale. It is investigational, and the long-term safety record is still being written.
Reference notes
- Receptor-selective by design: the earlier long-acting amylin analog cagrilintide also activates the calcitonin receptor; eloralintide was built to spare it.
- In the 48-week phase 2 obesity trial, weekly doses from 1 to 9 mg cut body weight by about 9.5% to 20.1% versus 0.4% on placebo — a GLP-1-class result from a non-incretin pathway.
- Gastrointestinal side effects were mostly mild to moderate; the trial had no GLP-1 comparator arm, so the tolerability edge the amylin field hopes for is suggested, not yet shown head-to-head.
- Paired with tirzepatide as the combination called EloraTZP: in a 48-week phase 2 trial in obesity with type 2 diabetes, the top dose reached about 23.3% weight loss versus 14.8% on tirzepatide 15 mg alone.
- Investigational — phase 3 trials are under way; not approved.
Regulatory status
United States · reviewed September 2026- Basis
- Phase 3 program (Eli Lilly) in obesity, alone and co-formulated with tirzepatide as EloraTZP; no approval.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Eloralintide?
- A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. Structurally it is Selective long-acting amylin analog (acylated 37 aa peptide).
- How does Eloralintide work?
- Eloralintide is a 37-residue amylin analog engineered for selectivity at the amylin receptor over the bare calcitonin receptor, stabilised against aggregation, and carrying a C20 fatty-diacid chain that binds albumin for a roughly two-week half-life. At the receptor it reproduces amylin's biology — slowed gastric emptying, suppressed post-meal glucagon, central satiety — without any GLP-1 receptor activity. It is the cleanest test yet of how far the amylin axis can go on its own, and is also being paired with tirzepatide. It is investigational.
- How strong is the evidence for Eloralintide?
- PeptideHormone grades Eloralintide at the "Investigational" evidence tier — it is under active human investigation — promising, but not yet settled. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of Eloralintide?
- The reported circulating half-life of Eloralintide is ~13–15 days (310–366 h).
- Is Eloralintide FDA-approved?
- No — as of September 2026, Eloralintide is in registered human trials but not approved for any indication. Phase 3 program (Eli Lilly) in obesity, alone and co-formulated with tirzepatide as EloraTZP; no approval. Status is US-centric and can change; check the FDA record for the current position.
In the literature
Live registry counts · retrieved- Ph 19
- Ph 24
- Ph 35
- Ph 40
Searched as Eloralintide. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on Eloralintide, not how it turned out.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial · Lancet (London, England), 2025 · PMID 41207310
- 2.Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept · Molecular metabolism, 2025 · PMID 41109426
- 3.Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept · Diabetes, obesity & metabolism, 2026 · PMID 41559929
External references
Eloralintide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.